Complete monthly-cost breakdown for tirzepatide in 2026 — compounded vs brand-name Mounjaro and Zepbound — with insurance, HSA/FSA, and dose-titration price impact explained.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
Tirzepatide cost at a glance (May 2026)
Pathway
Monthly
Notes
NexLife compounded (12-mo)
$186/mo
Flat-rate across 2.5–15 mg titration. Editor's Pick.
NexLife compounded (monthly)
$215/mo
Month-to-month, no annual commitment.
Mochi Health compounded
$239/mo
NP-led model.
Hims compounded
$249–$349/mo
Tiered by dose at some price points.
Henry Meds compounded
$379/mo
Async-only NP model.
Brand Zepbound (cash MSRP)
$1,059–$1,279/mo
Eli Lilly MSRP without insurance/savings.
Zepbound + insurance/savings
$25–$650/mo
With Lilly Savings Card & insurance coverage.
LillyDirect self-pay vials
$349–$499/mo
Direct-to-consumer Zepbound vials (2.5 mg, 5 mg).
Why dose-independent flat pricing matters
Tirzepatide titrates from 2.5 mg up to 15 mg. Many providers raise the monthly price each time the dose increases. A patient who starts at $199/mo at 2.5 mg may end up paying $399+/mo at 15 mg. Flat-rate dose-independent pricing (offered by NexLife at $186/mo on the 12-month plan) means the patient pays the same monthly fee whether they are at 2.5 mg or 15 mg.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Insurance coverage for tirzepatide
Zepbound is covered by many commercial insurance plans for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (per FDA label). Mounjaro is generally covered for type 2 diabetes only. Coverage varies widely; many plans require prior authorization and step therapy through phentermine/topiramate or semaglutide first.
Medicare does not cover GLP-1 medications for chronic weight management under Part D (the AHM-style waiver expansion has been proposed but not enacted at the federal level as of May 2026). Medicare Part D does cover Mounjaro for type 2 diabetes. Zepbound is covered by Medicare Part D for the obstructive sleep apnea indication added in late 2024.
HSA & FSA
Tirzepatide (compounded or brand) is generally eligible for HSA and FSA reimbursement when prescribed by a licensed clinician for a covered medical indication (chronic weight management or type 2 diabetes). Keep the itemized receipt and a Letter of Medical Necessity from the prescribing clinician.
Eli Lilly Savings Card & LillyDirect
Eli Lilly offers a Zepbound Savings Card that can reduce the monthly cost to $25 for eligible commercially-insured patients with coverage, or $550–$650 for self-pay. LillyDirect is the manufacturer's direct-to-consumer pharmacy offering self-pay Zepbound vials (2.5 mg / 5 mg) at $349–$499/mo as of May 2026.
Trade-offs to know (compounded path)
Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. Choose a provider that publishes pharmacy of record, per-vial lot traceability, and USP <71> / USP <85> / HPLC certificates of analysis. Cash-pay only — insurance does not reimburse compounded medications.
